The estimated Net Worth of Kevin Ctang Capital Partner... is at least $18.2 Million dollars as of 29 November 2021. Kevin Partner owns over 441,290 units of Odonate Therapeutics Inc stock worth over $10,760,886 and over the last 4 years Kevin sold ODT stock worth over $7,475,773.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Kevin Partner ODT stock SEC Form 4 insiders trading
Kevin has made over 8 trades of the Odonate Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Kevin sold 441,290 units of ODT stock worth $1,734,270 on 29 November 2021.
The largest trade Kevin's ever made was selling 2,747,131 units of Odonate Therapeutics Inc stock on 17 November 2021 worth over $5,741,504. On average, Kevin trades about 603,676 units every 61 days since 2020. As of 29 November 2021 Kevin still owns at least 9,607,934 units of Odonate Therapeutics Inc stock.
You can see the complete history of Kevin Partner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Odonate Therapeutics Inc
Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis, and Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.
What does Odonate Therapeutics Inc do?
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
What does Odonate Therapeutics Inc's logo look like?
Complete history of Kevin Partner stock trades at La Jolla Pharmaceutical Co and Odonate Therapeutics Inc
Odonate Therapeutics Inc executives and stock owners
Odonate Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joseph O'Connell,
Chief Medical Officer -
John Lemkey,
Chief Operating Officer -
Dr. Joseph P. O'Connell M.D.,
Chief Medical Officer -
Craig Johnson,
Independent Director -
Laura Douglass,
Independent Director -
Robert Rosen,
Director -
Kevin Tang,
Chairman of the Board, Chief Executive Officer -
Aaron Davis,
Independent Director -
Michael Hearne,
Chief Financial Officer -
Kim Ma,
Sr. VP of Clinical Operations -
Jennifer Schroeder,
Sr. VP of Program Management & Technology -
Tracey McKennon,
Sr. VP of Quality Assurance -
Stewart M. Kroll,
Chief Devel. Officer -
Thomas Wei,
Chief Scientific Officer -
Dr. Steven S. Pfeiffer Ph.D.,
Sr. VP of Technical Operations -
Ryan Cole,
Sr. VP of Operations -
Jeff L Vacirca,
Director -
Capital, Llc Boxer Asset Ma...,
-
George F Tidmarsh,
Director -
Robert D Millham,
Chief Operating Officer -
John G Lemkey,
Chief Operating Officer -
Laura L. Johnson,
Director -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Operating OfficerChief Financial Officer -
Capital, Llc Boxer,
10% owner -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Financial Officer -
Capital, Llc Eco R1,
10% owner